Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Cullgen Seeded with $15 Million from GNI, a Japan-China Biopharma

publication date: Mar 1, 2018

Cullgen, a US-Japan-China small-molecule drug startup, announced a Seed Financing of up to $15 million from GNI Group. Cullgen plans to develop drugs based on its ubiquitin-mediated protein degradation technology, which the company says will address previously undruggable targets. GNI is headed by Ying Luo, PhD, the founder of Shanghai Genomics, a company that was acquired by GNI. GNI has operations in Tokyo, Shanghai and Beijing. Dr. Luo will serve as President and CEO of Cullgen, which will initially focus on oncology and expand into inflammatory and autoimmune diseases. More details....

Stock Symbol: (TOKYO: 2160)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here